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Abstract
We introduce three assays for analyzing ligand-receptor interactions based on the specific conjugation of ligands to SNAP-
tag fusion proteins. Conjugation of ligands to different SNAP-tag fusions permits the validation of suspected interactions in
cell extracts and fixed cells as well as the establishment of high-throughput assays. The different assays allow the analysis of
strong and weak interactions. Conversion of ligands into SNAP-tag substrates thus provides access to a powerful toolbox for
the analysis of their interactions with proteins.
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Introduction
Methods for the detection of ligand-receptor interactions are a
crucial part of drug discovery and chemical biology in general [1–
5]. For the identification of the protein targets of a given ligand
(i.e. a drug or bioactive small molecule), affinity chromatography is
most commonly used [6]. If the purpose is the identification of
binders to a given protein, high-throughput-compatible approach-
es such as radioisotope-, fluorescence- or luminescence-based
detection methods are preferred [2,3]. For a detailed biophysical
characterization of a known ligand-receptor interaction, ap-
proaches such as isothermal titration calorimetry, surface plasmon
resonance, NMR or X-ray crystallography are chosen [4].
However, additional factors such as availability, purity, solubility,
and stability of the protein of interest influence the assay choice.
Overall, the development of suitable methods for the detection of
ligand-receptor interactions can still be a formidable challenge and
the availability of tools to rapidly establish a variety of
complementary assay systems would help to overcome this
challenge.
We recently introduced a SNAP-tag-based yeast three-hybrid
system for the identification of protein targets of drugs and
bioactive small molecules [7]. The approach is based on the
derivatization of a ligand with benzylguanine (BG); BG derivatives
can be specifically coupled to SNAP-tag fusion proteins in living
cells (Figure 1A) [8]. Coupling of the ligand to an appropriate
SNAP-tag fusion protein in yeast permits the screening of cDNA
libraries for its protein targets (Figure 1B) [7]. Furthermore, by
coupling ligands to SNAP-tag fusions that can be specifically
immobilized on beads, we also established a SNAP-based pull-
down assay using mammalian cell extracts (Figure 1B) [7]. Here
we build on these results and demonstrate how the coupling of BG
derivatives of ligands to different SNAP-tag fusion proteins can be
exploited to rapidly establish different assays based on either time-
resolved fluorescence resonance energy transfer (TR-FRET) [9],
selective crosslinking (S-CROSS) [10], or fluorescence microscopy
[11]. Together, these methods form a powerful toolbox for the
identification and analysis of ligand-receptor interactions based on
a single ligand derivative.
Results
SNAP-based TR-FRET Assay
To develop a method for the quantification of ligand-receptor
interactions that is also suitable for high-throughput applications,
we took advantage of both SNAP-tag and TR-FRET technology
using lanthanides (Figure 1B). By combining these two technol-
ogies, one can measure the affinity of both derivatized ligand and
free ligand for the receptor by simple titration (Figure 2) and
competition experiments (Figure 3), respectively. This assay is
highly sensitive, and is a simple ‘‘mix and measure’’ protocol
without washing step, which makes it easily applicable for a high-
throughput format.
In the SNAP-tag-based TR-FRET assay, as shown in Figure 2A,
a ligand was conjugated via SNAP-tag to EGFP acting as FRET
acceptor (tracer). Terbium-cryptate (Tb) connected to the receptor
protein via SNAP-tag formed the FRET donor [12,13]. The
excitation of Tb at a wavelength of 340 nm induces the emission
of fluorescence of long life-time (micro- to milliseconds) at a
maximum of 490 nm. Only when Tb and EGFP are in spatial
proximity (below 10 nm), EGFP emits fluorescence at a maximum
wavelength of 510 nm due to FRET.
To evaluate the performance of the method, we analyzed the
binding of methotrexate (MTX) to Escherichia coli dihydrofolate
reductase (eDHFR). The binding between MTX and eDHFR is
well characterized and a series of eDHFR mutants are available,
which bind to MTX with wide range of affinity [14,15]. We
prepared SNAP-tagged constructs of eDHFR wild-type (WT) and
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three eDHFR mutants (eDHFR L54I, eDHFR L54G and eDHFR
F31V, L54G) for which the reported Kd values to free MTX
range from low pM to low mM [16,17]. The dissociation constant
(Kd) of MTX-SNAP-EGFP (tracer) for SNAP-eDHFR (WT and
mutants) was measured with a tracer titration binding assay
(Figure 2A), using FRET signal readout and curve fitting based on
a single site binding model [18]. To facilitate assay preparation, an
excess of SNAP-eDFHR was incubated with BG-Tb and then
directly used without further purification. Background signal was
measured with SNAP-EGFP blocked with BG. The assay was
performed in the absence or presence of saturating concentration
of NADPH and at different concentrations of the receptor. Table 1
shows measured Kd values of SNAP-bound MTX. Representative
binding data using 1 nM receptor (without NADPH) and 0.1 nM
receptor (with 100 mM NADPH) are shown in Figure 2B. Kd
values from 0.4 nM to 13 mM could be determined with this assay;
the Kd between SNAP-bound MTX and eDHFR F31V, L54G in
the absence of NADPH was too high to measure. The data clearly
show that NADPH stabilizes the complex formation between
MTX tracer and eDHFR WT (8-fold), as well as eDHFR L54I
(180-fold), L54G (280-fold), or F31V, L54G (not calculated). It
should be noted that background signal increased at tracer
Figure 1. SNAP-based toolbox for detection and analysis of ligand-receptor interactions. (A) Covalent labeling of SNAP-tag with a ligand
using a BG derivative. (B) Schematic representation of the different SNAP-based methods. The highest Kd values detected in this study using the pairs
of MTX-eDHFR (WT and mutants) are presented for each method.
doi:10.1371/journal.pone.0037598.g001
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concentrations above 1 mM, especially at lower receptor concen-
tration (Figure 2B). This background signal might be due to a
nonspecific interaction either between Tb and the fluorophore, or
between the tracer and the receptor.
SNAP-based TR-FRET Competition Assay
The competition binding assay is based on the displacement of
the tracer from the tracer-receptor complex by an unmodified
compound, resulting in a decrease of the FRET signal (Figure 3A).
Applications of the competition TR-FRET assay include mea-
surement of Kd (or IC50) values of unlabeled ligands and high-
throughput screening. To evaluate the SNAP-based TR-FRET
assay in a competition binding mode, we analyzed the binding of
five known DHFR inhibitors to eDHFR (Figure 3B): the anti-
cancer drugs methotrexate and trimetrexate targeting human
DHFR, the anti-malaria drugs WR99210 and pyrimethamine
targeting plasmodium DHFR, and the anti-bacterial trimetho-
prim. Competition SNAP-based TR-FRET assay using MTX-
SNAP-EGFP as tracer and SNAP-eDHFR as receptor were
performed in the presence of saturating concentration of NADPH.
Kd values were calculated using a single site competitive binding
model of two different ligands to a receptor protein [19]. These
measurements showed that trimetrexate, pyrimethamine and
WR99210 are also inhibitors of eDHFR and the determined Kd
values of the five inhibitors for SNAP-eDHFR WT ranged from
Kd = 40 pM for methotrexate to Kd = 12 mM of WR99210
(Figure 3C; Table 2). Measurement of the Kd values of these
DHFR inhibitors for SNAP-eDHFR mutants L54I and L54G
revealed that Leu54 is important for methotrexate binding but not
for the binding of other DHFR inhibitors (Table 2 and Figure 3C).
Furthermore, the Kd values of MTX-BG were measured to
examine the influence of the derivatization of MTX on its affinity
for eDHFR (Figure S1). Notably, the derivatization of MTX with
BG decreased its Kd values for every eDHFR mutant about 10-
fold. The Kd values of MTX-tracer and MTX-BG for the SNAP-
eDHFR mutants were similar even though the molecular weight of
the tracer (SNAP-EGFP) is 52 kDa. We also determined the Z-
factor of the assay, a parameter typically used to evaluate the
suitability of an assay for high-throughput applications. Assays
with Z-factors between 0.5–1 are considered to be very well suited
for screening assays [20]. Under the conditions of Figure 3C, the
Z-factor was 0.75 (0.1 nM eDHFR WT and 1 nM tracer), 0.71
(0.1 nM eDHFR L54I and 2 nM tracer), and 0.83 (0.5 nM L54G
and 30 nM tracer), indicating that this assay is very well suited for
high-throughput applications (Figure S2). Finally, we compared
the results of the SNAP-based TR-FRET competition assay with
those obtained via a classical DHFR activity assay (Figure 3D and
Table 2). Measurement of IC50 values by an enzymatic assay
using 0.1 nM SNAP-eDHFR WT confirmed the data of the
SNAP-based TR-FRET competition assay.
Our next goal was the comparison of the performance of the
SNAP-based TR-FRET assay with a more traditional fluorescence
polarization (FP) assay. FP assays can be performed with
unmodified receptor protein but necessitate the protein in higher
concentrations. We used the previously identified interaction of
the kinase inhibitor erlotinib with oxysterol-binding protein-
related protein 7 (ORP7) to compare the two approaches [7].
We earlier measured its affinity by a FP assay using erlotinib
derivatized with tetramethylrhodamine (TMR) and SNAP-ORP7.
Titration and competition binding assays using 10 nM erlotinib-
TMR revealed a Kd value of 23063 nM, assuming single site
binding, and an IC50 of 101616 nM using erlotinib as a
competitor, respectively [7]. Since the range of resolvable IC50
in a FP assay is limited by the affinity of the tracer due to ligand
Figure 2. SNAP-based TR-FRET titration assay. (A) Scheme of the
titration binding assays. The titration assay measures the affinity of the
tracer for the receptor. (B) Titration assay using MTX-SNAP-EGFP (filled
rectangle) or SNAP-EGFP (empty rectangle) as tracer and SNAP-eDHFR
as receptor in the absence and presence of 100 mM NADPH. SNAP-
eDHFR is 50% labeled with BG-Terbium cryptate (Tb). Representative
data using receptor concentration of 1 nM (in the absence of NADPH)
and 0.1 nM (in the presence of NADPH) are shown. The specific
receptor concentration was chosen so that it was below the Kd of the
analyzed interaction. Kd values and the standard error of the mean are
shown in the graph. * indicates that the Kd values were calculated with
Fmax of the higher affinity samples (see Materials and Methods).
doi:10.1371/journal.pone.0037598.g002
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depletion [21], it is likely that the true IC50 of erlotinib for ORP7
is lower. The competition binding assay in SNAP-based TR-
FRET using the same protein concentration (250 nM erlotinib-
SNAP-EGFP for TR-FRET and 250 nM SNAP-ORP7 for FP
assay) revealed that the IC50 value of erlotinib actually was
10 nM, one order of magnitude lower than the value measured by
the FP assay (Figure 4). This demonstrates the superiority of TR-
FRET assays over traditional FP assays for those receptor proteins
that can be expressed as a (SNAP-tag) fusion protein. The
measured IC50 furthermore confirms ORP7 as a non-kinase off-
target of erlotinib.
Sensitivity of SNAP-based Pulldown Assay
In the SNAP-based pulldown assay (Figures 1B, 5A), the BG-
derivatized ligand is immobilized on glutathione-sepharose beads
by means of SNAP-tag fused with glutathione S-transferase (GST)
[7]. A pulldown is then performed using cell extract or purified
protein. Bound proteins are eluted with glutathione, and subjected
to SDS-PAGE analysis. The protein of interest can be then
detected by Western blotting or other methods.
We examined the sensitivity of the SNAP-based pulldown assay
with the SNAP-eDHFR mutants after preparation of MTX-
immobilized beads using BG-MTX. For the quantitative analysis
of bound proteins by in-gel fluorescence scanning after SDS-
PAGE [10], SNAP-eDHFR was labeled with BG-647. The 647-
SNAP-eDHFR (1 mM) was subjected to pulldown assay in the
absence and presence of 100 mM NADPH. Figure 5B is a
representative result of the pulldown assay using 647-SNAP-
eDHFR WT, which bound specifically MTX immobilized on
beads, irrespective of the presence or absence of NADPH. The
fluorescence signal of bound 647-SNAP-eDHFR WT and mutants
was quantified (Figure 5C), and the data showed that this assay is
able to detect the interaction of MTX with the eDHFR F31V,
Figure 3. SNAP-based TR-FRET competition assay. (A) Scheme of the competition binding assay. The competition assay measures the affinity
of the ligand for the receptor. (B) Chemical structures of DHFR inhibitors. MTX was linked to BG via the carboxyl group highlighted in red. (C) SNAP-
based TR-FRET competition assays using indicated concentrations of SNAP-eDHFR WT, L54I and L54G. Concentrations of MTX-SNAP-EGFP are 1 nM,
2 nM, and 30 nM for SNAP-eDHFR WT, L54I and L54G, respectively. Rectangle filled with black indicates dilution series of DMSO. Maximum DMSO
concentration is 0.5% at 100 mM compounds. (D) DHFR enzymatic activity inhibition assay using SNAP-eDHFR WT.
doi:10.1371/journal.pone.0037598.g003
Table 1. Dissociation constants of MTX-SNAP-EGFP for SNAP-
eDHFR measured by SNAP-based TR-FRET titration assay.
NADPH WT L54I L54G F31V, L54G
2 3.360.6 nM 140640 nM 1361 mM* .50 mM*
+ 0.4160.07 nM 0.7660.4 nM 4667 nM 1.960.1 mM*
Values are the mean6standard deviation (SD) from 2–6 independent
experiments. Receptor concentrations used in each experiment in the absence
of NADPH were 0.02, 0.3, 1 and 3 nM for WT, 0.3, 1 and 3 nM for L54I, 1 and
3 nM for L54G and F31V, L54G. Receptor concentrations used in the presence of
NADPH were 0.02, 0.03, 0.1 and 0.3 nM for WT, 0.1, 0.3 and 0.5 nM for L54I, 0.1,
0.5 and 30 nM for L54G and F31V, L54G. * indicates that Kd values were
calculated with Fmax of the higher affinity samples (see materials and
methods).
doi:10.1371/journal.pone.0037598.t001
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L54G in the presence of NADPH, but not the interaction of MTX
with eDHFR L54G in the absence of NADPH. Consequently, the
upper detection limit of SNAP-based pulldown assay for this
ligand-receptor pair is in the range of Kd values around 2 mM.
S-CROSS Assay
Given the limited sensitivity of the SNAP-based pulldown assay,
we wished to have a more sensitive binding assay than pulldown
for validation purposes. S-CROSS was originally developed in our
laboratory to detect protein-protein interactions [10]. In this assay,
the putative interacting proteins of interest X and Y are fused
respectively to SNAP-tag and CLIP-tag (another self-labeling
protein which specifically reacts with benzylcytosine (BC) deriv-
atives [22]). If the tagged proteins X and Y interact and are in
close spatial proximity, they can be hetero-crosslinked using
bifunctional molecules that contain both BG and BC attached to a
fluorophore. The hetero-crosslinking products are then detected
by SDS-PAGE followed by fluorescence scanning. To utilize this
assay for the detection of ligand-receptor interactions, the ligand is
attached to the SNAP moiety of a SNAP-CLIP protein, resulting
in the formation of the ligand-SNAP-CLIP where CLIP tag is
available for further modification with the cross-linker (Figures 1B,
6A).
Figure 6B shows a representative result of the S-CROSS assay
using SNAP-eDHFR WT (1 mM) and MTX-SNAP-CLIP (1 mM).
The band that migrated between 95–130 kDa appeared specifi-
cally in the lanes with MTX-SNAP-CLIP (regardless of the
presence or absence of NADPH) but not in the lanes with SNAP-
CLIP not attached to MTX. We therefore assigned this band to
the hetero-crosslinking product between SNAP-eDHFR WT and
MTX-SNAP-CLIP. Free MTX prevented the formation of the
hetero-crosslinking product. The same assay was performed with
all eDHFR mutants, and the quantification of the signal of the
hetero-crosslinking products is presented in Figure 6C. It was
possible to detect crosslinking with eDHFR L54G (without
NADPH) but not with the eDHFR F31V, L54G (without
NADPH). These results indicate that the upper detection limit
of S-CROSS lies in the range of Kd values of at least 13 mM,
which is more than 5-fold higher than that of our pulldown assays
(2 mM).
Another important property of a binding assay is the possibility
to perform it in cell extracts, in case that the interaction between a
ligand and a receptor require additional cellular factors. To
evaluate if the S-CROSS assay also is applicable in cell extracts,
we used extracts of HEK293 cells transiently expressing SNAP-
ORP7. Upon addition of erlotinib-SNAP-CLIP to the cell extract,
a new band migrating at 189 kDa was detected (Figure 6D),
indicating the formation of the hetero-crosslinking product of
SNAP-ORP7 and erlotinib-SNAP-CLIP. In the presence of free
erlotinib, this band was no longer detected. This experiment
therefore confirmed that the S-CROSS assay is also applicable to
analyze ligand-protein interactions in cell extracts.
Cell Imaging Assay
Finally, we developed a binding assay applicable to fixed cells.
Such an assay is desirable if the protein to be analyzed is insoluble
or unstable in extracts. In this assay (Figure 1B, 7A), the epitope-
tagged receptor protein is over-expressed in mammalian cells by
transient transfection. The cells are fixed with paraformaldehyde
and permeabilized with nonionic detergent. The expression of the
receptor protein is then confirmed by visualization with the anti-
epitope tag antibody conjugated with a fluorophore using
immunofluorescence microscopy. In parallel, the ligand-protein
interaction is examined with the aid of BG-derivatized ligand
conjugated to EGFP via SNAP-tag. Fluorescence micrographs
(anti-V5-ab-FITC) in Figure 7B show that the transiently
overexpressed V5-tagged ORP7, labeled with FITC-conjugated
anti-V5 antibody, is localized in the cytoplasm of the transfected
cells, consistent with reported data [23]. A similar cytoplasmic
localization of V5-ORP7 was visualized with erlotinib-SNAP-
EGFP but not with SNAP-EGFP (data not shown). This
demonstrates that it is possible to detect the erlotinib-ORP7
Table 2. Dissociation constants of DHFR inhibitors measured by SNAP-based TR-FRET competition assay.
Enzymatic assay IC50 (nM)
WT
Kd (nM)
WT
Kd (nM)
L54I
Kd (nM)
L54G
MTX 0.07160.007 0.04060.004 0.1360.01 6.960.4
Trimetrexate 0.2760.03 0.1560.01 0.1060.01 0.6460.04
Trimethoprim 0.5360.09 0.3060.02 0.1060.01 0.3860.03
Pyrimethamine 19006220 260619 1461 3962
WR99210 54000616000 120006950 26006210 150006790
IC50 and Kd values are the mean6standard error (N = 3 and 4, respectively).
doi:10.1371/journal.pone.0037598.t002
Figure 4. SNAP-based TR-FRET competition assay for ORP7-
erlotinib interaction. The assay was performed at indicated
concentrations of SNAP-ORP7 (receptor) and erlotinib-SNAP-EGFP
(tracer) with erlotinib as a competitor. IC50 values and the standard
error of the mean are shown.
doi:10.1371/journal.pone.0037598.g004
Toolbox to Monitor Ligand-Receptor Interactions
PLoS ONE | www.plosone.org 5 May 2012 | Volume 7 | Issue 5 | e37598
interaction in paraformaldehyde-fixed cells. We evaluated the
generality of this method using other previously validated drug-
protein interactions (PDE6D-atorvastatin, PTK2B-purvalanol B,
and FYN-dasatinib). Binding of all three pairs was detected with
this method (Figure S3).
Discussion
Despite the availability of numerous conceptually different
approaches to identify and characterize ligand-receptor interac-
tions, there is a need for alternative methodologies that are both
sensitive and suitable for applications with either isolated proteins
or in complex mixtures. We introduce here three different assays
for analyzing ligand-receptor interactions based on the specific
conjugation of BG-labeled ligands to SNAP-tag fusion proteins.
SNAP-tag fusions provide the ligand-protein conjugate with
functionalities that either enable the detection of ligand-receptor
interactions in high-throughput assays or the validation of
suspected interactions in cell extracts or fixed cells. The approach
is based on the assumption that the ligand can be derivatized with
BG and coupled to SNAP-tag without abolishing its affinity for the
receptor protein. All three assays were tested using different,
previously identified ligand-protein interactions [7]; each interac-
tion pair we tested was confirmed by our assays.
The first assay we introduce is particularly well suited for a
quantitative analysis of ligand-receptor interactions. In this TR-
FRET assay the ligand is coupled to a SNAP-EGFP fusion protein
that functions as the FRET acceptor of a terbium-cryptate which
was coupled to the receptor protein via SNAP-tag. Using this
approach, we were able to detect interactions ranging from
0.4 nM to 13 mM in tracer titration experiments. It should be
noted that the efficiency of the SNAP-tag labeling reaction makes
a purification of the labeled SNAP-tag fusions unnecessary,
thereby facilitating the implementation of the assay. Furthermore,
the high sensitivity of the SNAP-based TR-FRET assay makes it
well suited for high-throughput screening. The SNAP-based
competition binding assay is especially useful when simple
enzymatic assays are not available for the protein of interest.
The second assay we introduce is particularly well suited for a
validation of suspected ligand-receptor interactions in cell lysates.
It is based on a selective crosslinking (S-CROSS) assay in which
the ligand is coupled to a SNAP-CLIP fusion protein and then
selectively crosslinked to the suspected target protein that is
expressed as a SNAP-tag fusion protein. The key features of S-
CROSS are its high sensitivity, permitting the detection of Kd
values above 10 mM in favorable cases, as well as the fact that it
can be performed in cell lysates. This makes it an attractive
alternative to more traditional pulldown assays, even if the latter
can also be utilized to detect endogenous proteins.
The third assay is a cell imaging assay utilizing fixed cells and a
ligand bound to a SNAP-EGFP fusion protein for fluorescence
staining. The assay appears particularly well suited for proteins
that cannot be (easily) expressed as soluble and stable proteins.
The cell imaging assay can be performed with a small number of
cells and is experimentally simple and fast.
In addition to these three assays, we previously introduced a
SNAP-based yeast three-hybrid system as well as a SNAP-based
pulldown assay. The synthesis of a BG derivative of a given ligand
therefore creates access to a powerful toolbox that permits: (i) the
search for the target proteins of ligands, (ii) the validation of
identified interactions in cell lysates or fixed cells, (iii) the
quantification of ligand-receptor interactions, and (iv) the estab-
lishment of robust assays for high-throughput application.
Furthermore, the possibility to express numerous other SNAP-
tag fusion proteins should allow the design of additional assays.
Ligand-protein conjugates should therefore become important
tools in the analysis of ligand-receptor interactions.
Figure 5. SNAP-based pulldown assay for detection of ligand-
receptor interactions. (A) Scheme of the pulldown assay. The BG-
ligand is immobilized on glutathione sepharose beads via GST-SNAP.
Bound receptor proteins are concentrated on the beads after
incubation with the extract and washing. (B) SNAP-eDHFR WT labeled
with BG-647 (1 mM) was subjected to pulldown assay in the absence or
presence of 100 mM NADPH using MTX immobilized on beads (MTX-BG
+) or mock beads (MTX-BG -). Bound proteins were eluted with
glutathione, submitted to SDS-PAGE and detected by in-gel fluores-
cence scanning. (C) Fluorescence signal of bound proteins normalized
with the input signal in each gel (Mean6SD, n = 3). # represents
P = 0.03 in paired t-test.
doi:10.1371/journal.pone.0037598.g005
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Materials and Methods
Reagents
The synthesis of methotrexate-BG (MTX-BG) and BG-erlotinib
using O6-benzylguanine-(PEG)4-NH2 was described previously
[24]. SNAP-Cell Fluorescein (BG-fluorescein), SNAP-Cell TMR-
Star (BG-tetramethylrhodamine), SNAP-Surface 647 (BG-647)
were provided by NEB. BG derivatized with terbium cryptate
(BG-Tb, SNAP-Lumi4-Tb) was provided by Cisbio Bioassays.
Stocks of all compounds were prepared in DMSO and stored at
220uC.
Cell Culture
U2OS cells (ATCC, HTB-96) were cultured in DMEM
supplemented with 10% fetal bovine serum [7]. Suspension-
adapted HEK-293E cells obtained from David Hacker (EPFL,
Switzerland) were cultured in EX-CELL293 serum-free medium
(SAFC Biosciences) with 6 mM L-glutamine [25].
Plasmids
The E.coli expression plasmid pET-His-SNAP-eDHFR was
constructed by DNA recombination with the destination plasmid
pET-His-SNAP/DEST and gateway entry plasmid pENTR221-
eDHFR using LR clonase II Enzyme mix (Invitrogen). pET-His-
SNAP/DEST was constructed by insertion of the DNA sequence
of SNAP-tag between the DNA sequence of the hexa-histidine
tag and the DNA sequence of attR1 site of pDEST17
(Invitrogen). pENTR221-eDHFR (WT and mutants) was con-
structed by DNA recombination between pDONR221 (Invitro-
gen) and PCR products containing ORF of eDHFR flanked with
Figure 6. S-CROSS assay for the detection of ligand-receptor interactions. (A) Scheme of the S-CROSS assay. SNAP-receptor and ligand-
SNAP-CLIP are incubated to form a complex. BG-fluorophore-BC preferentially crosslinks proteins that are in close spatial proximity. (B) SNAP-eDHFR
WT (1 mM) was mixed with MTX-SNAP-CLIP or unlabeled SNAP-CLIP (1 mM) in the presence or absence of free MTX (50 mM). The experiments were
performed in the absence or presence of 100 mM NADPH. Then, the mixture was treated with 2.5 mM BG-647-BC. Labeled proteins were resolved by
SDS-PAGE and detected by in-gel fluorescence scanning. (C) Fluorescence signal of the hetero-crosslinking products in the presence or absence of
free MTX (Mean6SD, n = 3–5). # represents P = 0.001 in paired t-test. (D) S-CROSS assay in cell extract. SNAP-ORP7 was expressed in HEK293 cells.
After preparation of extract, SNAP-ORP7 was subjected to S-CROSS assay using erlotinib-SNAP-CLIP (2 mM) in the absence or presence of free erlotinib
(10 mM).
doi:10.1371/journal.pone.0037598.g006
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attB sites (pGAD-HA-eDHFR was used as PCR template [7])
using BP clonase II (Invitrogen). The E.coli expression plasmid
pET51b-SNAP-EGFP (A207K) expresses SNAP-EGFP (A207K)
with hexa-histidine and strep-tags at amino and carboxyl
terminus, respectively. EGFP (A207K) mutant (corresponds to
YFP (A206K) in the reference [26]) was chosen to prevent
possible homo-dimerization of EGFP at high protein concentra-
tion. The EGFP sequence originally derived from pEGFP-TUB
(CLONTECH) was replaced with the CLIP sequence of
pET51b-SNAP-CLIP [27]. Then, the A207K mutation was
introduced with overlap PCR. pET51b-SNAP-EGFP was used
for the cell imaging assay, while pET51b-SNAP-EGFP (A207K)
was used for the TR-FRET assay. Construction of pcDNA3.1-
V5-SNAP/DEST and pcDNA3.1-V5-ORP7 was previously
described [7]. Construction of pcDNA3.1-Strep-SNAP/DEST
was performed as described in construction of pcDNA3.1-Flag-
SNAP/DEST but with oligonucleotides containing single strep-
tag sequence (WSHPQFEK) [7].
Preparation of Recombinant Proteins
SNAP-eDHFR (WT and mutants) were expressed from pET-
His-SNAP-eDHFR in E.coli BL21, and purified by Ni-NTA
affinity chromatography. These proteins were further purified with
a Superdex S200 10/300GL column (GE healthcare) in buffer A
(50 mM Hepes-NaOH pH 7.4, 150 mM NaCl, 10% glycerol, and
1 mM DTT), and stored at 280uC. SNAP-ORP7 tagged with
strep-tag at the amino terminus was expressed as described by
Backliwal et al [25,28]. Two days after transfection, HEK293 cells
were collected and lysed in the presence of 10 cell pellet volume of
lysis buffer (50 mM Tris-HCl pH 7.9, 150 mM NaCl, 5 mM
EDTA, 1% Triton X-100, and protease inhibitor cocktail
(Complete Mini, Roche)) at room temperature for 15 min. The
extract was cleared by centrifugation at 15 krpm for 15 min at
4uC, and the supernatant was dialyzed against buffer (0.1 M Tris-
HCl pH 7.9, 150 mM NaCl, and 1 mM EDTA) using 14 kDa
MWCO dialysis membrane (SPECTRUM). The extract was
subjected to affinity chromatography using Strep-tactin sepharose
column (IBA) according to the manufacturer’s instructions.
Purified SNAP-ORP7 was dialyzed against buffer A. Purity of
SNAP-ORP7 prepared in this way was .90%, as determined by
Figure 7. Cell imaging assay for detection of ligand-receptor interactions. (A) Scheme of the cell imaging assay. The receptor protein is
transiently expressed in mammalian cells. Cells are fixed with 4% paraformaldehyde, and then permeabilized with detergent. Ligand-SNAP-EGFP is
incubated with the cells. Immediately after washing, samples are analyzed with a fluorescence microscope. (B) Fluorescence micrographs of U2OS
cells transiently expressing V5-ORP7 probed with FITC-conjugated anti-V5 antibody (left) and erlotinib-SNAP-EGFP (right) by cell imaging assay (FITC
filter in green). Nuclear staining with Hoechst 33342 is shown in blue (UV filter).
doi:10.1371/journal.pone.0037598.g007
Toolbox to Monitor Ligand-Receptor Interactions
PLoS ONE | www.plosone.org 8 May 2012 | Volume 7 | Issue 5 | e37598
SDS-PAGE and Coomassie brilliant blue (CBB) staining. SNAP-
EGFP (A207K) was expressed from pET51b-SNAP-EGFP
(A207K) and induced in E.coli BL21 using auto-induction medium
ZYP-5052 [29], purified with a Ni-NTA affinity column and
subsequent Strep-tactin sepharose column chromatography, and
then dialyzed against buffer A. The purity, estimated by SDS-
PAGE and CBB staining, was more than 95%. SNAP-CLIP was
expressed from pET51b-SNAP-CLIP [27] and purified as SNAP-
EGFP.
Determination of Concentration of Reagents
The concentration of MTX and MTX-BG was determined
based on e (373 nm) = 7800 cm21 M21. The protein concentra-
tions were determined using the absorbance at 280 nm based on
the extinction coefficient (e= 56170 cm21 M21 of SNAP-eDHFR,
e= 46300 cm21 M21 of SNAP-CLIP) calculated from the amino
acid sequences. The concentration of SNAP-EGFP (A207K) was
determined based on e (488 nm) = 68000 cm21 M21 of EGFP
(A207K). This extinction coefficient was determined experimen-
tally by comparison with SNAP-EGFP WT (e
(488 nm) = 55000 cm21 M21) using the absorbance at 280 nm
and 488 nm of the two proteins. The molar ratio of active SNAP
and fluorescent EGFP of the purified SNAP-EGFP (A207K) was
measured as follows. SNAP-EGFP was labelled with 2-fold excess
BG-647 for complete labeling, then unreacted substrate was
removed by NAP5 gel filtration column (GE healthcare). The
absorbance of the labelled protein at 488 nm and 650 nm was
measured, and concentration of EGFP (A207K)
(e(488 nm) = 68000 cm21 M21) and fluorophore 647 (e
650 nm) = 250000 cm21 M21) was calculated. Measured ratio
was approximately 1. The concentration of SNAP-ORP7 was
determined by labeling with BG-647 and subsequent in-gel
fluorescence scanning (BIO-RAD) and by comparison to reference
protein samples using the Quantity One software (BIO-RAD).
TR-FRET Assay
SNAP labeling experiments with BG-substrate were performed
at room temperature for 1 h. Partial labeling of the SNAP-
receptor with BG-Tb (Cisbio Bioassays) was performed by mixing
1 mM receptor protein and 0.5 mM BG-Tb in buffer A supple-
mented with 0.5 mg/ml BSA and 0.05% Triton X-100. We
performed partial labeling with BG-Tb to avoid additional
purification steps to remove excess BG-Tb. SNAP-EGFP
(A207K) was completely labeled with 2-fold molar excess of BG-
ligand in buffer A. Free BG-ligand was removed by NAP5 gel
filtration column. The concentration of ligand-SNAP-EGFP
(A207K) was determined using absorbance at 488 nm (e
(488 nm) = 68000 cm21 M21). The aliquots of receptor and tracer
were stored at 280uC. The yield of SNAP labeling was
characterized as follows. The purified ligand-labeled SNAP fusion
protein was mixed with 10 mM BG-fluorescein or BG-tetra-
methylrhodamine (TMR), both of which have fast reaction rates.
Under these conditions, all the unreacted SNAP is then
fluorescently labeled with the fast-reacting BG-fluorophore. The
fluorescently labeled SNAP fusion protein and protein standards of
SNAP fusion protein labeled with same BG-fluorophore for
quantification were resolved by SDS-PAGE and detected by in-gel
fluorescence scanning.
In the titration assay, SNAP-eDHFR partially labeled with BG-
Tb was mixed with 3-fold dilution series of MTX-SNAP-EGFP or
SNAP-EGFP blocked with BG in buffer A supplemented with
0.5 mg/ml BSA and 0.05% Triton X-100 in the absence or
presence of 100 mM NADPH in a final volume of 70 ml. A
receptor concentration was lower than the corresponding Kd
value to prevent ligand depletion. Aliquots of 20 ml were
transferred in 3 wells of a black 384 well plate (Corning 3820).
Signal was measured 1 h later in the titration assay by EnVision
(PerkinElmer). An excitation filter of 320 nm and emission filters
of 486 nm and 510 nm were used. Delay time and time windows
were set to 120 ms and 400 ms, respectively.
In the competition assay, 10 ml of pre-formed mixture of BG-Tb
labeled SNAP-eDHFR and MTX-SNAP-EGFP in 26buffer E
(0.1 M Hepes-NaOH pH 7.4, 0.3 M NaCl, 1 mg/ml BSA, 0.1%
TritonX-100, 2 mM DTT and 0.1 mM NADPH) were trans-
ferred in a well of 384 well plates, and then 10 ml of 5-fold serial
dilutions of compounds prepared in water were added in
quadruplicate. Plates were sealed and left at room temperature
in the dark for 4 days (SNAP-eDHFR WT) and 3 h (SNAP-
eDHFR L54I and L54G) until measurement of signal. Time
course experiments showed that it took 4 days for SNAP-eDHFR
WT and 2 h for SNAP-eDHFR L54I and L54G to reach
equilibrium (Figure S4). Z-factor was calculated using water and
1 mM trimethoprim as negative and positive control, respectively,
using the equation previously described [20]. DHFR enzymatic
assay was performed by following decrease of absorbance at
340 nm for 1 h at room temperature in transparent 96 well plates.
50 ml of enzyme mixture containing 0.4 nM SNAP-eDHFR WT
in 4 6 buffer E was added to a well. Then, 50 ml of 5-fold serial
dilution of compounds prepared in water was added. The reaction
was started by addition of 100 ml of 80 mM dihydrofolic acid in
10 mM Hepes-NaOH (pH 7.4). The assays were performed in
triplicate. Data points for 1 h were used for determination of
enzyme activity.
Curve Fitting
The Kd value of the tracer for SNAP-eDHFR was calculated by
fitting to the full equation of single site binding with the effect of
nonspecific binding [18].
y~ Fmax{Fminð Þ:FsbzFminzN:x
with
Fsb~
(LzxzKd{
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
LzxzKdð Þ2{4L:x
q
2L
In the equations, the dependent variable x is the concentration
of the tracer and the dependent variable y is the emission signal at
510 nm. L is the total concentration of the receptor and Kd is the
dissociation constant. N is a parameter of nonspecific interaction
between the tracer and the receptor and/or between the
fluorophore and Tb. Fmax and Fmin are respectively the
maximum and minimum values of emission signal when N = 0.
Global fitting was performed for Figure 2B using OriginPro 8.5
software. Kd value of SNAP-EGFP (A207K) blocked with BG for
SNAP-eDHFR was fixed to 100 mM and not infinite, since the
statistical evaluation was more satisfactory. The Kd values with
asterisk in Figure 2 and Table 1 were too high to precisely fit
without restriction of a parameter Fmax, which was taken from
higher affinity mutants with the assumption that Fmax is the same
for SNAP-eDHFR WT and mutants.
The Kd value of competitor for SNAP-eDHFR was calculated
by fitting to full equation of single site competitive binding [19]. In
the competition assay, emission ratio (defined as emission signal at
510 nm from EGFP normalized with emission signal at 486 nm
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from Tb-cryptate) was used to minimize the inner filter effect
caused by higher concentration of some compounds.
y~Fminz(Fmax{Fmin):Rv=R
with
a~KdzKizTzI{R
b~Ki T{Rð ÞzKd I{Rð ÞzKd:Ki
c~{Kd:Ki:R
h~arccos
{2a3z9a:b{27c
2(a2{3b)1:5
 
Rv~
T 2
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
(a2{3b)
p
:cos(h=3){a
n o
3Kdz 2
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
(a2{3b)
p
:cos(h=3){a
n o
In the equations, the dependent variable I is the concentration
of the competitor and the dependent variable y is the emission
ratio. Kd is the dissociation constant of the tracer for the receptor,
Ki is the dissociation constant of the competitor for SNAP-
eDHFR, T is the total tracer concentration, and R is the total
receptor concentration. Fmax and Fmin are the maximum and
minimum values of emission ratio, respectively.
Pulldown Assay
SNAP-based pulldown assay was performed as previously
described [7], but with modification of the detection method for
the target proteins. SNAP labeling was performed for 20–30 min at
room temperature. 20 ml of 20% sepharose 4B slurry in buffer B
(50 mM Tris-HCl pH 7.9 and 0.5 M NaCl) were mixed with 60 ml
of E. coli extract containing bead-saturating amounts of GST-SNAP
and incubated for 30 min at 4uC with rotation. The beads were
then washed twice with 1 ml buffer A and resuspended in 50 ml of
the same buffer. The immobilized GST-SNAP was labeled with
MTX-BG (10 mM) with rotation. After the incubation, unreacted
GST-SNAP was blocked with an excess of O6-BG (SIGMA). After
blocking, the beads were washed twice with 200 ml buffer A. The
recombinant SNAP-eDHFR (1 mM) was labeled with 10 mM BG-
647 in buffer A to allow in-gel visualization of the proteins. Then,
the unreacted SNAP was blocked by addition of 100-fold excess O6-
BG. 5 ml of each labeled protein were used for the input (10% of the
total). Immobilized MTX-SNAP-GST and SNAP-GST were
incubated with 647-SNAP-eDHFR in the presence and absence
of 100 mM NADPH in a final volume of 50 ml. The beads were
incubated for 2 h at 4uC with rotation. After washing twice with
200 ml buffer A, the bound proteins were eluted with 20 ml of
50 mM Tris-HCl pH 7.9 supplemented with 10 mM reduced
glutathione for 15 min at room temperature. The eluted proteins
were resolved in 12% SDS polyacrylamide gels and visualized by in-
gel fluorescence scanning. The fluorescence intensity of the bands
was quantified with the Quantity one software.
S-CROSS Assay
SNAP-CLIP (5 mM) in buffer A was labeled with MTX-BG
(10 mM) for 1 h at room temperature. Then free MTX-BG was
removed by NAP-5 column purification using buffer A. MTX-
SNAP-CLIP (1 mM) and SNAP-eDHFR (1 mM) were mixed in the
absence and presence of 100 mM NADPH and/or 50 mM free
MTX in buffer A in a final volume of 20 ml for 1 h at room
temperature. Then the cross-linker BG-Cy5-BC [10] (2.5 mM) was
added and the reactions were incubated for 1 h at 37uC. The
reactions were stopped by addition of SDS sample loading buffer
and incubation for 5 min at 95uC. The proteins were analyzed as
described for pulldown assay.
Cell Imaging Assay
U2OS cells in a m-Dish (Ibidi) were transfected with pcDNA3.1-
V5-ORP7 using Lipofectamine 2000 reagent (Invitrogen) and
cultured for 48 h. Following procedures were performed at room
temperature. The cells were washed twice with PBS and fixed with
4% paraformaldehyde pH 7.0 in PBS for 10 minutes. After
washing three times with PBS, the cells were permeabilized with
0.1% Triton X-100 in PBS for 5 minutes. The cells were then
washed twice and blocked with 1% non-fat milk in PBS for 30
minutes. Expression of the V5-tagged protein was confirmed by
immunofluorescence microscopy with the a-V5-FITC conjugated
antibody (Invitrogen), diluted 1:1000 in PBS, for 2 h in the dark.
SNAP-EGFP was completely labeled with BG-erlotinib as
described above and eluted in PBS. The fixed cells were incubated
for 2 h with 250 mL of 500 nM erlotinib-SNAP-EGFP or
unlabeled SNAP-EGFP in 1% non-fat milk-PBS. Hoechst 33342
(0.1 mg/ml) was added 10 minutes before the imaging for nuclear
staining. The cells were then washed with PBS 3 times and imaged
within 30 min after washing using a 1206 objective with a Zeiss
Axiovert 200 inverted microscope equipped with an AxioCam
MR digital camera (Zeiss).
Supporting Information
Figure S1 SNAP-based TR-FRET competition assay
using MTX and MTX-BG as competitors in the presence
of 100 mM NADPH. Kd values and the standard error of the
mean are shown in the graph.
(DOCX)
Figure S2 Z-factor of the assay setup of Figure 3B.
Emission ratio was measured in the absence and presence of 1 mM
trimethoprim in the assay setup of Figure 3C (concentrations of
receptor and tracer are indicated), and plotted against number of
wells. Indicated Z-factors were calculated from the data.
(TIF)
Figure S3 Cell imaging assay using validated drug-
receptor pairs. (A) U2OS cells were transfected with a plasmid
which express V5 tagged PDE6D. One day after transfection, cells
were fixed with 4% paraformaldehyde, and permeabilized with
0.1% Tritin X-100. After washing, the cells were incubated with
anti-V5-antibody conjugated with FITC or 100 nM atorvastatin-
SNAP-EGFP. Fluorescence images (GFP filter) were taken within
30 min after washing of the cells. (B) (C) Cell imaging assay using
pairs of purvalanol B-PTK2B and dasatinib-FYN, respectively.
(TIF)
Figure S4 Time-course experiments of SNAP-based TR-
FRET competition binding assay. (A) A mixture containing
90 pM SNAP-eDHFR WT and 1.2 nM MTX-SNAP-EGFP were
prepared as described in materials and methods. At indicated time
after addition of methotrexate, emission signal at 510 nm and
486 nm wavelengths was measured. Emission ratio (emission
signal at 510 nm divided by emission signal at 486 nm) was plotted
against concentration of methotrexate. (B) The same experiment
as (A) was performed in parallel with 90 pM of SNAP-eDHFR
L54I and 2.2 nM of MTX-SNAP-EGFP.
(TIF)
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